MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Biogen Inc.

< Previous 1 2 3 4 Next >
News headline image
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen to Acquire Reata Pharmaceuticals
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB RETA
News headline image
Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB IONS
News headline image
Biogen Announces Changes to Its Board of Directors
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Appoints Adam Keeney as Head of Corporate Development
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB SAGE
News headline image
Lecanemab Receives Priority Review Status in Japan
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Names Priya Singhal as Executive Vice President, Head of Development
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB IONS
News headline image
Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Names Christopher Viehbacher President and Chief Executive Officer
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
New Data at ECTRIMS 2022 Highlight Biogen’s Commitment to Advancing Individualized Disease Management for People Living with MS
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story